The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose

Objective  Low glucagon‐like peptide‐1 (GLP‐1) concentrations have been observed in impaired fasting glucose (IFG). It is uncertain whether these abnormalities contribute directly to the pathogenesis of IFG and impaired glucose tolerance. Dipeptidyl peptidase‐4 (DPP‐4) inhibitors raise incretin hormone concentrations enabling an examination of their effects on glucose turnover in IFG.

[1]  Claudio Cobelli,et al.  Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes , 2009, Diabetes Care.

[2]  F. Toledo,et al.  Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[3]  J. Holst,et al.  The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. , 2008, Diabetes care.

[4]  T. Hansen,et al.  Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study , 2008, Diabetologia.

[5]  Michael Camilleri,et al.  Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes , 2007, Diabetes.

[6]  Claudio Cobelli,et al.  Effects of Nonglucose Nutrients on Insulin Secretion and Action in People With Pre-Diabetes , 2007, Diabetes.

[7]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[8]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[9]  W. Zeng,et al.  Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses , 2005, Clinical pharmacology and therapeutics.

[10]  D. Pereg,et al.  Normal fasting plasma glucose levels and type 2 diabetes in young men. , 2005, The New England journal of medicine.

[11]  M. Hanefeld,et al.  Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. , 2005, Metabolism: clinical and experimental.

[12]  Claudio Cobelli,et al.  Measurement of selective effect of insulin on glucose disposal from labeled glucose oral test minimal model. , 2005, American journal of physiology. Endocrinology and metabolism.

[13]  A. Tura,et al.  Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. , 2004, Metabolism: clinical and experimental.

[14]  J. Holst,et al.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  T. Hughes,et al.  Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. , 2002, The Journal of endocrinology.

[16]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[17]  C Cobelli,et al.  Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. , 2001, Diabetes.

[18]  Claudio Cobelli,et al.  Oral Glucose Tolerance Test Minimal Model Indexes of β-Cell Function and Insulin Sensitivity , 2001 .

[19]  M. Stumvoll,et al.  Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion , 2000, Diabetologia.

[20]  C. Bogardus,et al.  Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. , 1999, Diabetes.

[21]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[22]  M. Beylot,et al.  Determination of the 13C-labeling pattern of glucose by gas chromatography-mass spectrometry. , 1993, Analytical biochemistry.

[23]  Jeppe Sturis,et al.  Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance , 1992, Diabetes.

[24]  R. Steele,et al.  Glucose Uptake and Production During the Oral Glucose Tolerance Test , 1968, Diabetes.